202 related articles for article (PubMed ID: 27471124)
1. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
Hansen IO; Sørensen AL; Hasselbalch HC
Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124
[TBL] [Abstract][Full Text] [Related]
2. Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms.
Mondello P; Di Mirto C; Cuzzocrea S; Arrigo C; Mian M; Pitini V
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e489-e495. PubMed ID: 31231012
[TBL] [Abstract][Full Text] [Related]
3. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
Wang R; Shallis RM; Stempel JM; Huntington SF; Zeidan AM; Gore SD; Ma X; Podoltsev NA
Blood Adv; 2023 Mar; 7(5):734-743. PubMed ID: 35917456
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms.
Lindgren M; Samuelsson J; Nilsson L; Knutsen H; Ghanima W; Westin J; Johansson PL; Andréasson B
Eur J Haematol; 2018 May; 100(5):419-425. PubMed ID: 29369421
[TBL] [Abstract][Full Text] [Related]
5. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
6. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
7. Can pegylated interferon improve the outcome of polycythemia vera patients?
Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
[TBL] [Abstract][Full Text] [Related]
8. A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2.
Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Ellervik C; Larsen MK; Kjaer L; Skov V; Hasselbalch HC; Ottesen JT
Cancer Med; 2023 Feb; 12(4):4218-4226. PubMed ID: 36254099
[TBL] [Abstract][Full Text] [Related]
9. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
10. Second malignancies in philadelphia-negative myeloproliferative neoplasms-single-center experience.
Kissova J; Ovesna P; Penka M; Bulikova A; Kiss I
Anticancer Res; 2014 May; 34(5):2489-96. PubMed ID: 24778065
[TBL] [Abstract][Full Text] [Related]
11. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Nielsen I; Hasselbalch HC
Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
[TBL] [Abstract][Full Text] [Related]
12. Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide.
Ahn IE; Natelson E; Rice L
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S300-4. PubMed ID: 24290215
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.
Antonioli E; Guglielmelli P; Pieri L; Finazzi M; Rumi E; Martinelli V; Vianelli N; Luigia Randi M; Bertozzi I; De Stefano V; Za T; Rossi E; Ruggeri M; Elli E; Cacciola R; Cacciola E; Pogliani E; Rodeghiero F; Baccarani M; Passamonti F; Finazzi G; Rambaldi A; Bosi A; Cazzola M; Barbui T; Vannucchi AM;
Am J Hematol; 2012 May; 87(5):552-4. PubMed ID: 22473827
[TBL] [Abstract][Full Text] [Related]
14. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
[TBL] [Abstract][Full Text] [Related]
15. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
16. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
17. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
Radaelli F; Onida F; Rossi FG; Zilioli VR; Colombi M; Usardi P; Calori R; Zanella A
Hematology; 2008 Aug; 13(4):195-202. PubMed ID: 18796244
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
Litam PP; Landaw SA; Zamkoff KW
Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
[TBL] [Abstract][Full Text] [Related]
20. Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.
Riley CH; Jensen MK; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM
Blood; 2011 Aug; 118(8):2170-3. PubMed ID: 21708889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
